Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient
Final published version, 737 KB, PDF document
Recent advances in mass spectrometry (MS)-based technologies are now set to transform translational cancer proteomics from an idea to a practice. Here, we present a robust proteomic workflow for the analysis of clinically relevant human cancer tissues that allows quantitation of thousands of tumor proteins in several hours of measuring time and a total turnaround of a few days. We applied it to a chemorefractory metastatic case of the extremely rare urachal carcinoma. Quantitative comparison of lung metastases and surrounding tissue revealed several significantly upregulated proteins, among them lysine-specific histone demethylase 1 (LSD1/KDM1A). LSD1 is an epigenetic regulator and the target of active development efforts in oncology. Thus, clinical cancer proteomics can rapidly and efficiently identify actionable therapeutic options. While currently described for a single case study, we envision that it can be applied broadly to other patients in a similar condition.
Original language | English |
---|---|
Journal | Molecular Oncology |
Volume | 12 |
Issue number | 8 |
Pages (from-to) | 1296-1307 |
Number of pages | 12 |
ISSN | 1574-7891 |
DOIs | |
Publication status | Published - 2018 |
- case study, clinical proteomics, epigenetics, mass spectrometry, urachal carcinoma
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 198265634